Lunit highlights ai-powered IHC and tumor microenvironment research at ASCO 2026. May 21, 2026 At ASCO 2026, Lunit will present precision patient stratification and biomarker-driven oncology research through AI-powered HER2/IHC biomarker quantification and spatial tumor microenvironment analysis. SEOUL, South Korea, May 22, 2026 /PRNewswire/ - Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announces that five studies featuring its AI biomarker platforms are being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago, IL. Lunit at ASCO 2026 This year's presentations reflect Lunit's expanding biomarker research beyond conventional immune profiling toward integrated AI-powered HER2/IHC biomarker quantification and spatial tumor microenvironment (TME) analysis. Using AI to characterize HER2 expression, immune phenotypes, tertiary lymphoid structures (TLS), tumor-infiltrating lymphocytes (TILs), and endothelial cells, the studies highlight the potential of integrated biomarker analysis to improve precision patient stratification across multiple cancer types. The five presentations include studies across biliary tract cancer (BTC), non-small cell lung cancer (NSCLC), adenoid cystic carcinoma (ACC), microsatellite-stable (MSS), metastatic colorectal cancer and advanced gastric cancer (AGC). One of the featured studies, led by researchers at Yonsei University College of Medicine, evaluates a first-line quadruplet regimen consisting of trastuzumab, nivolumab, gemcitabine, and cisplatin in HER2-positive advanced BTC. The study is selected as a Rapid Oral Presentation at ASCO 2026. Using AI-powered whole-slide image (WSI) analysis, researchers analyze HER2 expression and immune phenotypes within tumor tissue. Among 40 patients enrolled in the multi-center phase Ib/II trial, the combination of therapy demonstrates an objective response rate (ORR) of 55%, disease control rate (DCR) of 95%, and median progression-free survival (PFS) of 10.6 months. Patients with HER2 IHC 3+ tumor cell proportions >=10%, as identified by AI analysis, achieve substantially higher response rates compared to those below the threshold (80% vs. 36.4%). The study demonstrates how integrated AI-powered HER2 and spatial tumor microenvironment analysis may help identify patients more likely to benefit from HER2-targeted combination therapies. Another study characterizes the tumor microenvironment landscape of HER2-overexpressing NSCLC using AI-powered spatial analysis. Across more than 2,000 NSCLC whole-slide images, HER2-overexpressing tumors demonstrate significantly reduced tumor-infiltrating lymphocyte density and lower proportions of inflamed immune phenotype compared to non-overexpressing tumors. The immune-cold phenotype becomes more pronounced in tumors with higher proportions of HER2 3+ cells. The study provides additional insight into the biological relationship between HER2 overexpression and tumor immune status, while highlighting the broader potential of combining AI-powered HER2 analysis with spatial tumor microenvironment characterization in biomarker research. Another featured study, conducted with Seoul National University Hospital, explores AI-powered spatial tumor microenvironment analysis in adenoid cystic carcinoma (ACC), a rare cancer with limited treatment options. Researchers identify a subgroup of ACC patients with high endothelial cell and tumor-infiltrating lymphocyte (TIL) densities who demonstrate significantly prolonged progression-free survival following axitinib treatment (19.6 months vs. 11.1 months). The findings suggest that AI-based spatial profiling may help distinguish responder populations that are difficult to stratify using conventional biomarkers alone. Researchers at Asan Medical Center investigate AI-powered tumor microenvironment analysis in MSS metastatic colorectal cancer, which is generally considered resistant to immune checkpoint inhibitors (ICIs). Researchers find that patients with larger tertiary lymphoid structure (TLS) regions identified by AI demonstrate improved progression-free survival and overall survival following immunotherapy. The findings highlight the potential of AI-powered spatial analysis to identify MSS colorectal cancer patients more likely to benefit from immunotherapy. "These studies demonstrate how AI-powered biomarker analysis is evolving beyond conventional immune profiling toward integrated HER2/IHC quantification and spatial tumor microenvironment analysis," said Brandon Suh, CEO of Lunit. "We believe integrated biomarker analysis will play an increasingly important role in precision oncology research, patient stratification, and treatment-response assessment." Lunit will be exhibiting at ASCO 2026, where attendees can learn more about the company's AI biomarker platforms and research collaborations. Lunit's featured AI biomarker studies at ASCO 2026 include: About Lunit Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Its clinically validated solutions span medical imaging, breast health, and biomarker analysis - empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum. Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Its FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development. Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact - for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

Lunit, a medical AI company, has completed an oversubscribed rights offering worth 211.5 billion won, achieving a 104.7% subscription rate. During the two-day subscription period, 8,278,502 shares were subscribed, exceeding the planned issuance of 7,906,816 shares. The strong demand was driven by institutional investors, including Atinum Investment, which invested 30 billion won after acquiring management's subscription rights. Lunit will use the funds to address financial risks, including put option risks on convertible bonds issued during its Volpara acquisition and concerns over pre-tax losses. CEO Seo Beom-seok stated the company aims to achieve EBITDA profitability by year-end. New shares are scheduled to list on 15 May, followed by a bonus share issue.

Lunit Surpasses 330+ Sites and 1M Annual screenings as Breast Imaging AI moves into clinical practice. 2026-04-16 20:00 724 Lunit highlights enterprise AI adoption and FDA-cleared advancements at SBI 2026 SEOUL, South Korea, April 16, 2026 /PRNewswire/ - At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced accelerating clinical adoption across the U.S., a full-scale enterprise deployment of its AI-powered breast cancer ecosystem, and FDA clearance of its next-generation 3D mammography AI. Lunit x Lexington Clinic Lexington Clinic Adopts Full Breast Cancer Ecosystem Lexington Clinic, Central Kentucky's largest and oldest physician-owned multi-specialty medical group (serving more than 350 providers), has implemented Lunit's complete AI-powered breast cancer ecosystem. The deployment spans: * Detection with Lunit INSIGHT(R) Breast Suite for mammography (MMG) and digital breast tomosynthesis (DBT) * Quality optimization with Analytics(TM) and Volpara(R) Live(TM) * Volumetric breast density assessment with Volpara(R) Scorecard(TM) * Risk assessment with Risk Pathways(TM), integrated into clinical workflows * Mammography tracking with Patient Hub(TM) The implementation signals a shift toward end-to-end AI integration across the breast care continuum - from risk to detection to quality - within a single software suite. "Our goal is to deliver the highest standard of care while keeping workflows efficient and consistent," said Angie Hall, Breast Center Manager at Lexington Clinic. "Bringing risk, detection, and quality into one ecosystem improves coordination across our team and supports more confident, earlier decision-making for every patient." Adoption Across the Americas Surpasses 330 Sites Over the past year, Lunit has expanded to more than 330 screening sites across the Americas, supporting approximately one million screening mammograms annually. The milestone highlights a broader industry shift: while AI validation is well established, real-world adoption at scale is now the key differentiator. "Across the Americas, we're seeing a clear move from evaluation to enterprise-wide implementation," said Craig Hadfield, CEO of Lunit International. "Providers are moving beyond pilots into daily clinical use. Reaching more than 330 sites and supporting one million screenings annually reflects sustained, real-world adoption - where AI is delivering value in routine practice." Real-World Clinical Impact: Radiology Consultants of Iowa At Radiology Consultants of Iowa (RCI), one of the largest radiology groups in the state, Lunit INSIGHT DBT is already embedded in routine clinical workflows, demonstrating the impact of AI beyond the study setting. "After six months of using AI in our daily workflow, it's become part of how we read," said Robert J. Dolan, DO, breast imaging specialist at RCI. "It gives us added confidence - especially in subtle cases - and helps ensure we don't miss what matters most." At SBI, Dr. Dolan will review cases each day in Lunit's booth, highlighting where AI positively impacts his interpretation, giving attendees a chance to discuss real-world adoption. FDA Clearance of Next-Generation 3D AI with Current-Prior Comparison As providers move into routine AI use, flexibility in how algorithms are deployed is becoming increasingly important. Lunit announced that Version 1.2 of its 3D mammography algorithm has received clearance from the U.S. Food and Drug Administration (FDA). The updated version introduces current-prior comparisons and multiple operating thresholds, enabling providers to tailor AI performance to their clinical environment. Key enhancements include: * Current-prior comparison (CPC) provides AI findings for the current exam and up to two prior exams * Three selectable thresholds, supporting different sensitivity and specificity trade-offs * Access to Volpara(R) Scorecard(TM) volumetric breast density measures along with AI scores These updates reinforce Lunit's focus on practical usability - giving clinicians greater control over how AI is applied in daily practice. About Lunit Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Its clinically validated solutions span medical imaging, breast health, and biomarker analysis - empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum. Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Its FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development. Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact - for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.